Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Lumos Pharma, Inc. LUMO NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
54/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$16.50
+280.2%

Lumos Pharma, Inc. (LUMO) is a Biotechnology company in the Healthcare sector, currently trading at $4.34. It has a SharesGrow Score of 54/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is LUMO = $17 (+280.2% upside).

Financials: revenue is $2M, +211.2%/yr average growth. Net income is $34M (loss), growing at -149.7%/yr. Net profit margin is -1659.4% (negative). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $585,000 against $27M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 5.69 (strong liquidity). Debt-to-assets is 1.4%. Total assets: $41M.

Analyst outlook: 4 / 7 analysts rate LUMO as buy (57%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 46/100 (Partial), Future 64/100 (Pass), Income 10/100 (Fail).

$16.50
▲ 280.18% Upside
Average Price Target
Based on 7 Wall Street analysts offering 12-month price targets for Lumos Pharma, Inc., the average price target is $16.50, with a high forecast of $26.00, and a low forecast of $7.00.
Highest Price Target
$26.00
Average Price Target
$16.50
Lowest Price Target
$7.00

LUMO SharesGrow Score Overview

63/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 64/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — LUMO

✓
VALUE Pass
100/100
LUMO trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $17, implying +291.7% from the current price $4. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
LUMO: +211.2%/yr revenue is, -149.7%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet LUMO: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 5.69 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
LUMO: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
64/100
Analyst outlook: 4 / 7 analysts rate LUMO as buy (57%). Analyst consensus target is $17 (+291.7% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
LUMO: Net profit margin is -1659.4%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range1.3701-4.5756
Volume390.87K
Avg Volume (30D)102.98K
Market Cap$37.54M
Beta (1Y)0.33
Share Statistics
EPS (TTM)-4.18
Shares Outstanding$8.15M
IPO Date2011-11-11
Employees30
CEORichard J. Hawkins
Financial Highlights & Ratios
Revenue (TTM)$2.05M
Gross Profit$2.05M
EBITDA$-36.57M
Net Income$-34.03M
Operating Income$-36.61M
Total Cash$36.08M
Total Debt$585K
Net Debt$-34.49M
Total Assets$40.64M
Price / Earnings (P/E)-1
Price / Sales (P/S)18.3
Analyst Forecast
1Y Price Target$16.50
Target High$26.00
Target Low$7.00
Upside+280.2%
Rating ConsensusBuy
Analysts Covering7
Buy 57% Hold 43% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS55028X1090

Price Chart

Track all markets on TradingView
LUMO
Lumos Pharma, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
1.37 52WK RANGE 4.58

People Also View

ERAS
ERAS
Erasca, Inc.
$18.20
+1.96%
 FBRX
FBRX
Forte Biosciences, Inc.
$31.28
-3.52%
 RZLT
RZLT
Rezolute, Inc.
$3.59
+1.13%
 STTK
STTK
Shattuck Labs, Inc.
$7.17
+5.75%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
 IPSC
IPSC
Century Therapeutics, Inc.
$2.59
+9.28%
 THRX
THRX
Theseus Pharmaceuticals, Inc.
$4.07
+0.12%
 PRDS
PRDS
Pardes Biosciences, Inc.
$2.18
+0.93%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message